Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30350% above fair value
$73.71−0.82 (-1.10%)
Close on Nov 12, 2026Market cap $7.97BP/E 175.5Yield –
Corcept Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Corcept Therapeutics's enterprise value was $8.30B on Nov 11, 2026, against $9.09B a year earlier. Over the last 5 years it ranged from $1.81B to $13.01B, with a median of $3.38B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.30B | +121.7% |
| 2025 | Dec 31, 2025 | $3.75B | -28.4% |
| 2024 | Dec 31, 2024 | $5.23B | +57.7% |
| 2023 | Dec 29, 2023 | $3.32B | +67.0% |
| 2022 | Dec 30, 2022 | $1.99B | -7.8% |
| 2021 | Dec 31, 2021 | $2.15B | -22.9% |
| 2020 | Dec 31, 2020 | $2.79B | +122.0% |
| 2019 | Dec 31, 2019 | $1.26B | -16.4% |
| 2018 | Dec 31, 2018 | $1.51B | -24.2% |
| 2017 | Dec 29, 2017 | $1.99B | +155.9% |
| 2016 | Dec 30, 2016 | $775.86M | +45.1% |
| 2015 | Dec 31, 2015 | $534.74M | +71.8% |
| 2014 | Dec 31, 2014 | $311.29M | +6.7% |
| 2013 | Dec 31, 2013 | $291.87M | +418.0% |
| 2012 | Dec 31, 2012 | $56.35M | -76.0% |
| 2011 | Jul 29, 2011 | $234.63M | – |
See a number that looks wrong?